ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.03
+0.43 (+1.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close38.60
Open38.90
Bid36.38 x 3000
Ask43.60 x 1200
Day's Range38.74 - 39.14
52 Week Range38.23 - 71.22
Volume637,768
Avg. Volume607,401
Market Cap6.061B
Beta2.61
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.58
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why Alkermes plc (NASDAQ:ALKS) Is A Financially Healthy Company
    Simply Wall St.7 days ago

    Why Alkermes plc (NASDAQ:ALKS) Is A Financially Healthy Company

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkermes plc (NASDAQ:ALKS), with a market cap of US$6.23b, are often out of the spotlight.Read More...

  • Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
    Zacks8 days ago

    Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo

    Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.

  • PR Newswire9 days ago

    Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

    DUBLIN, Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the FDA-approved PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. ALKS 4230 is an engineered fusion protein designed to preferentially bind and signal through the intermediate affinity interleukin-2 (IL-2) receptor complex, thereby selectively activating and increasing the number of immunostimulatory tumor-killing immune cells while avoiding the expansion of immunosuppressive cells that interfere with anti-tumor response.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    Alkermes PLC NASDAQ/NGS:ALKS

  • Alkermes: Product Portfolio Performance Update
    Market Realist14 days ago

    Alkermes: Product Portfolio Performance Update

    In the second quarter, Alkermes’ (AKLS) Aristada generated revenues of $33.6 million—compared to $22.7 million in the second quarter of 2017, which reflects~48% growth YoY (year-over-year).

  • How’s Alkermes Positioned Financially in September?
    Market Realist14 days ago

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.

  • Alkermes: Analysts’ View in September
    Market Realist14 days ago

    Alkermes: Analysts’ View in September

    Alkermes (ALKS) anticipates the net revenues in fiscal 2018 to be $957.0 million–$1.0 billion. Alkermes estimates the GAAP (generally accepted accounting principle) net income to be -$210.0 million to -$240.0 million, while the GAAP EPS is expected to be -$1.35 to -$1.55. Alkermes expects the non-GAAP net income to be between -$10 million and $20 million. The company also estimates the non-GAAP EPS to be between -$0.06 and $0.12.

  • Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
    PR Newswire14 days ago

    Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

    DUBLIN, Sept. 5, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the company is now accepting applications for the 3rd annual ALKERMES INSPIRATION GRANTS® program. The competitive program will award up to $1 million in grants to various organizations for the implementation of innovative, high-impact and replicable programs designed to make a positive difference in the lives of people affected by mental health and substance use disorders.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Investopedia26 days ago

    3 Biotech Stocks That May Rise as Much as 16%

    Biotech stocks have put together a solid year as measured by the iShares Nasdaq Biotechnology ETF ( IBB). Shares of Alkermes PLC ( ALKS), BeiGene Ltd. ( BGNE) and Nektar Therapeutics Inc. ( NKTR ), are three stocks in the ETF that could help to lead the way higher for the rest of the sector over the coming months. BeiGene is nearly 21% off its 2018 highs of nearly $220, but shares have found a strong level of technical support at roughly $154.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realistlast month

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realistlast month

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Alkermes settles gender bias lawsuits for undisclosed amounts
    American City Business Journalslast month

    Alkermes settles gender bias lawsuits for undisclosed amounts

    Alkermes opted to settle the two complaints before they reached trial for undisclosed sums, with at least one including a confidentiality agreement.

  • ANIK vs. ALKS: Which Stock Is the Better Value Option?
    Zackslast month

    ANIK vs. ALKS: Which Stock Is the Better Value Option?

    ANIK vs. ALKS: Which Stock Is the Better Value Option?

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire2 months ago

    Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

    DUBLIN , Aug. 1, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, ...

  • Collaborations Help Alkermes Flip to Profitability
    Motley Fool2 months ago

    Collaborations Help Alkermes Flip to Profitability

    The commercial-stage biopharma posts revenue growth of 39% thanks to increased product sales and a sizeable milestone payment.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALKS earnings conference call or presentation 26-Jul-18 12:30pm GMT

    Q2 2018 Alkermes Plc Earnings Call

  • Associated Press2 months ago

    Alkermes: 2Q Earnings Snapshot

    The Dublin-based company said it had a loss of 21 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, came to 29 cents per share. The results topped Wall Street expectations. ...

  • See what the IHS Markit Score report has to say about Alkermes PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alkermes PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire2 months ago

    Alkermes Plc Reports Second Quarter 2018 Financial Results

    -- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 ...

  • Benzinga2 months ago

    Earnings Preview: Alkermes

    Don't be caught off-guard: Alkermes (NASDAQ: ALKS ) releases its next round of earnings this Thursday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters ...